Association between nociplastic pain and premature endocrine therapy discontinuation in breast cancer patients.

ABSTRACT:

Purpose

At least 5 years of adjuvant endocrine therapy (ET) is recommended for patients with hormone receptor-positive invasive breast cancer to reduce cancer recurrence risk. Up to half of patients prematurely discontinue ET, often due to musculoskeletal pain. Nociplastic pain is abnormal central nervous system pain processing without evidence of tissue or neuronal damage. This study aimed to evaluate the relationship between baseline nociplastic pain and ET discontinuation.

Methods

This was a retrospective, single center, cohort study. Included patients were female, had stage 0-III invasive breast cancer, did not receive neoadjuvant therapy, and completed quality of life questionnaires prior to breast surgery, including Fibromyalgia Survey for nociplastic pain. Clinical da

SUBMITTER: Joyce E 

PROVIDER: S-EPMC9825644 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature